Abstract: The present disclosure generally relates to a combination therapy comprising an anti-clusterin antibody or antigen binding fragment thereof and a taxane and its use in the treatment of subjects having non-small cell lung cancer (NSCLC). The combination therapy may be used for treating NSCLC patients including, NSCLC patients that have failed prior treatment that comprises an immune checkpoint antibody, NSCLC patients having one or more lesions showing low expression of programmed death ligand 1 (PD-L1), NSCLC patients having no evidence of PD-L1 expression or NSCLC patients that are not eligible for or would unlikely benefit from treatment comprising an anti-PD-1 or anti-PD-L1 immune checkpoint antibody.

Abstract: The present invention provides a novel method for treating a patient with cancer comprising administering to the patient a therapeutically effective amount of cisplatin and a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and a hydroxy protecting group.

Abstract: In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of cancer comprising at least one active compound of formula (I): and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents; and, a method of treating a patient having cancer comprising at least one active compound of formula (I), as defined above, and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents.

Abstract: In the treatment of cancer, troxacitabine or a pharmaceutically acceptable salt can be effectively administered to a host having a tumor by continuous infusion for a period of at least 72 hours, wherein said amount is sufficient to provide tumor reduction.

Abstract: In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of cancer comprising at least one active compound of formula (I): and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents; and, a method of treating a patient having cancer comprising at least one active compound of formula (I), as defined above, and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents.

Abstract: The present invention provides a novel method for treating leukemia in a host that has been previously treated with a Bcr-Abl tyrosine kinase inhibitor comprising administering to the host a therapeutically effective amount of a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and and where in each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl an hydroxy protecting group.

Abstract: The present invention provides a novel method for treating leukemia in a host that has been previously treated with a Brc-Abl tyrosine kinase inhibitor comprising administering to the host a therapeutically effective amount of a compound having the formula I: 1

Abstract: In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of cancer comprising at least one active compound of formula (I): 1

Abstract: The present invention provides a novel method for treating a patient with cancer comprising administering to the patient a therapeutically effective amount of cisplatin and a compound having the formula I: 1

Abstract: The present invention relates to a cDNA probe for the detection of the mRNA for human methenyltetrahydrofolate synthetase, which comprises the nucleic acid sequence as shown in FIG. 6 or any functional analogs thereof wherein the hybridization of the probe and the mRNA for human methenyltetrahydrofolate synthetase is substantially preserved. The present invention also relates to a polyclonal antibody or an antigen-binding fragment thereof for the detection of the mRNA for human methenyltetrahydrofolate synthetase, wherein said antibody is raised against a protein segment aa.sup.100-112 H-Phe-Asp-Lys-His-Gly-Asn-Arg-Leu-Gly-Lys-OH of human methenyltetrahydrofolate synthetase.

Abstract: The present invention relates to a cDNA probe for the detection of the mRNA for human methenyltetrahydrofolate synthetase, which comprises the following nucleic acid sequence, Seq. Id. No. 1: ##STR1## or any functional analogs thereof wherein the hybridization of the probe and the mRNA for human methenyltetrahydrofolate synthetase is substantially preserved. The present invention also relates to a polyclonal antibody or an antigen-binding fragment thereof for the detection of the mRNA for human methenyltetrahydrofolate synthetase, wherein said antibody is raised against a protein segment aa.sup.100-112 H-Phe-Asp-Lys-His-Gly-Asn-Arg-Leu-Gly-Arg-Gly-Lys-OH, Seq. Id. No. 2 of human methenyltetrahydrofolate synthetase.